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Abstract
Genetic factors have been estimated to account for about 25% of the variation in an adult’s life span. The complement
component C4 with the isotypes C4A and C4B is an effector protein of the immune system, and differences in the overall C4
copy number or gene size (long C4L; short C4S) may influence the strength of the immune response and disease
susceptibilities. Previously, an association between C4B copy number and life span was reported for Hungarians and
Icelanders, where the C4B*Q0 genotype, which is defined by C4B gene deficiency, showed a decrease in frequency with age.
Additionally, one of the studies indicated that a low C4B copy number might be a genetic trait that is manifested only in the
presence of the environmental risk factor ‘‘smoking’’. These observations prompted us to investigate the role of the C4
alleles in our large German longevity sample (,700 cases; 94–110 years and ,900 younger controls). No significant
differences in the number of C4A, C4B and C4S were detected. Besides, the C4B*Q0 carrier state did not decrease with age,
irrespective of smoking as an interacting variable. However, for C4L*Q0 a significantly different carrier frequency was
observed in the cases compared with controls (cases: 5.08%; controls: 9.12%; p = 0.003). In a replication sample of 714
German cases (91–108 years) and 890 controls this result was not replicated (p = 0.14) although a similar trend of decreased
C4L*Q0 carrier frequency in cases was visible (cases: 7.84%; controls: 10.00%).
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Introduction
Human longevity is considered a multi-factorial phenotype, and
genetic factors have been estimated to account for about 25% of
the variation in adult life span [1,2,3,4,5]. Nonagenarians and
centenarians have outlived the vast majority of their peers by
many decades. Most of them have spent their life in good health
and often markedly delay or even escape major age-related
diseases [6,7]. It has been postulated that these long-lived
individuals (LLI) carry a reduced number of risk alleles for age-
related diseases [8,9]. A case in point is the apolipoprotein E*e4
allele (risk factor for Alzheimer’s and coronary heart disease) that is
significantly depleted in LLI [1].
Complement C4 is a central component of the mannose-
binding lectin activation pathways of the complement system that
are main effectors of the adaptive and innate immune responses
[10,11,12]. The C4 protein exists as two isotypes, the acidic C4A
and basic C4B form. They are encoded by the C4A and C4B genes
located in the major histocompatibility complex (MHC) class III
region. C4A and C4B differ from each other only at five single
nucleotide polymorphisms (SNPs) [13,14]. Although the resulting
isotypes are antigenetically quite similar (.99% amino acid
sequence identity), they exhibit functional differences, for instance
in chemical reactivities to substrates [15,16,17,18,19]. Further-
more, it is thought that the C4A protein is more important in
immunoclearance, whereas C4B is more relevant in the defense
against microbes [17].
Both C4A and C4B genes are found with varying copy numbers
(CNVs), as indicated by the Database of Genomic Variants
(http://projects.tcag.ca/variation) [15]. The total number of C4A
and C4B genes can range between two and eight (considering
homologous chromosomes). While most healthy subjects carry two
C4A and two C4B genes each [15,16,17], heterozygous deficiency
of C4A or C4B has been described in up to 30% of populations of
European descent [20]. C4B gene deficiency (zero or one C4B
gene in the diploid genome) is traditionally called C4B*Q0 and the
corresponding situation for C4A is denoted as C4A*Q0 [12,15]. In
addition, both C4 genes differ in size; they can be short (C4S) or
long (C4L; due to the insertion of 6.4 kb from the endogenous
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retrovirus HERV-K) [21]. In Caucasians about 76% of the C4
genes belong to the long form and 24% to the short form [18,20].
C4L/C4S gene deficiency is called C4S*Q0 or C4L*Q0, respec-
tively. The copy number and the size of C4 genes strongly
determine the plasma C4 protein concentrations and linear
correlations between total C4, C4A and C4B gene copy number
with their corresponding plasma protein concentration were
observed [22]. For instance, individuals containing one or more
short C4 genes have consistently higher serum total C4
concentrations than those with long C4 genes only, suggesting a
negative epistatic effect of HERV-K retrovirus on the expression
of C4 proteins [18].
The frequent variations in C4 size and numbers render the gene
an interesting marker for major histocompatibility complex disease
associations [23,24,25,26]. Expression and overall gene copy
numbers of total C4, C4A, C4B or the C4 gene size (C4S or C4L)
may influence the strengths of innate or adaptive immunity and
disease susceptibilities [15,16,18,27,28,29]. A low C4B copy
number has been shown to be a risk factor for cardiovascular
diseases [15,30,31,32,33,34,35]. Furthermore, a study by Kramer
et al. revealed that a low C4B allele frequency is associated with a
shortened life span. The authors observed a significant decrease in
C4B*Q0 alleles among healthy old Hungarians (.62 years)
compared to a younger (,53 years) control group (from 18%
allele frequency in the young, which equals 36% carrier frequency;
to 5% allele frequency in the elderly, corresponding to 10% carrier
frequency) [36]. In a follow-up study in 1991, Kramer et al.
supported their previous findings. They detected a marked
decrease in the C4B*Q0 allele frequency (p,0.0001) in a second
sample of old Hungarian study participants (.60 years: 5%;
equals 10% carrier frequency) compared to younger individuals
(,45 years: 16%; equals 32% carrier frequency). To test if this
observation was population-specific for the two investigated
Hungarian samples, a second collaborative experiment in 381
healthy Icelandic people, including 73 healthy elderly individuals
(.59 years) was performed. In this independent replication
sample, a significant decrease in the C4B*Q0 carrier frequency
was found in the elderly group from 24% to 5% [37]. In a
subsequent Icelandic follow-up study, however, no statistically
significant age-associated decrease was detected for the C4B*Q0
carrier frequency [30]. Because smoking severely affects health
and survival on a global scale [38,39], the authors tested whether
the increased risk of early morbidity observed in carriers of
C4B*Q0 could be associated with smoking as an interacting
variable. After dividing the whole Icelandic sample into smokers
and non-smokers, a significant decrease in C4B*Q0 carrier
frequency with age (17–39 years: 19%, 40–49 years: 20%, 50–
59 years: 4%, 60–93 years: 0%; x2 test for trend; p = 0.0079) was
seen only among smokers, indicating that C4B low copy number
might be a genetic trait that is manifested only in the presence of
the environmental risk factor ‘‘smoking’’ [30]. All data on C4B
copy number variation in Hungarians and Icelanders are
summarized in Szilagyi et al. 2008 [15]. In an Italian study
sample of 77 centenarians (100–107 years), 89 elderly subjects
(70–89 years) and 235 young subjects (18–49 years) the negative
influence of C4B*Q0 alleles on life span was not confirmed [40].
Here, we employed our large study sample of German
individuals to i) investigate the role of C4 copy number variation
in human longevity, to ii) potentially validate the association of
C4B*Q0 carrier state with life span and to iii) test the hypothesis of
‘‘smoking’’ as an effecting variable. About 700 LLI between 94
and 110 years of age and approximately 900 younger individuals
(19–75 years) have been analyzed for the C4A, C4B, C4S and C4L
allele distribution. To evaluate whether differences in C4B*Q0
carrier frequency could be detected in smokers, we additionally
performed a stratified analysis for smokers and non-smokers.
Materials and Methods
Study participants
In this study, we investigated ,700 LLI (male/female ratio
approximately 1/1; age-range 94–110 years) and ,900 younger
controls (male/female ratio approximately 1/1; age-range 19–
75 years) drawn from German population-based collections
Figure 1. Frequencies of C4B*Q0 carriers (with zero or one C4B gene in the diploid genome) in healthy German individuals of
different age-groups. p_case_contr: p value for the comparison of C4B*Q0 carrier frequencies between long-lived cases and younger controls
(Fisher’s exact test; primary endpoint). p_contr_trend: p value for trend test of C4B*Q0 carrier frequencies in the three control subgroups (Armitage
trend test; secondary endpoint). p_case: p value for the comparison of C4B*Q0 frequencies in the two case subgroups (Fisher’s exact test; secondary
endpoint). p_trend: p value for trend test of C4B*Q0 frequencies in all five age groups (Armitage trend test; secondary endpoint).
doi:10.1371/journal.pone.0086188.g001
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[41,42] for C4 copy number variation. The proportion of recent
smokers was a little above 3% for LLI and a little below 40% for
controls. A detailed description of the samples and the recruitment
procedure is given elsewhere [43] and in Supplementary
Table S1a and S1b in File S1.
The sample used to investigate the C4L alleles in the replication
experiment comprised 714 LLI (male/female ratio approximately
1/10; age-range 91–108 years) and 890 controls (male/female
ratio approximately 1/10; age-range 18–79), for details see
Supplementary Table S1a and S1b in File S1.
All participants gave written informed consent to participate
within the study. Approval for the project was obtained by the
Ethics Committee of the Medical Faculty of the Christian-
Albrechts-University, Kiel.
Genotyping
Genotyping of C4 copy numbers (determination of C4A, C4B,
C4L, and C4S dosage) was performed using the TaqMan
chemistry-based real-time PCR technique (C4A, Hs07226349;
C4B, Hs07226350; C4L, Hs07226352; C4S, Hs07226351) (Life
Technologies Corporation, Foster City, CA) [16]. For each sample
four replicates were genotyped and samples with data for fewer
than three replicates were excluded from further analyses. All copy
number data are listed in Data S1.
Statistical analyses
The copy number calculation was performed using the Copy-
CallerTM Software (Life Technologies Corporation, Foster City,
CA). The copy number assignment was cross-checked internally
for each individual as the sum of C4A copies plus C4B copies
should equal the sum of C4L copies plus C4S copies. If the equality
Figure 2. Frequencies of C4B*Q0 carriers in healthy German individuals of different age-groups stratified for (a) smokers (current
smokers and quitters ,3 years) and (b) non-smokers (never smokers and quitters for $3 years). For abbreviations see legend to
Figure 1. Due to the small number of centenarians in the replication sample we did not subdivide the case sample into a nonagenarian and
centenarian subgroup.
doi:10.1371/journal.pone.0086188.g002
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was violated, the corresponding individual was excluded from the
analyses. Further quality control for each CNV calling included: a)
removal of all samples with analysed replicate number 0, 1 or 2; b)
removal of all samples with confidence ,0.95 and |CNpredicted-
CNcalculated| .0.3.; c) removal of all samples with z score$2.65
and d) removal of all samples with 2.65.z score $1.75 and
|CNpredicted-CNcalculated| .0.3. (criteria for quality control
were adopted from the CopyCaller Software User Guide (PN
4400042B)). Sample sizes before and after quality control are given
in Supplementary Table S1a and S1b in File S1.
Allele and carrier frequencies were compared between long-
lived cases and younger controls by Fisher’s exact test. For the
comparison of the different age subgroups, the Armitage trend test
was applied. To evaluate whether differences in C4B*Q0 carrier
frequency were detected in smokers, we performed a stratified
analysis for smokers and non-smokers. For C4A, C4B, C4L, and
C4S*Q0 carrier frequencies, we additionally applied a sex-stratified
analysis.
Primary endpoint of the initial study was the comparison of the
C4B*Q0 carrier frequency between LLI and controls, possibly after
stratifying for smoking. Secondary endpoints were the C4A, C4L
and C4S*Q0 carrier frequency differences between cases and
controls and the comparison along three to five age subgroup by a
trend analysis. For the replication sample, the C4L*Q0 carrier
frequency comparison between LLI and controls served as
primary endpoint while the trend analysis over four age subgroups
again was the secondary endpoint.
The data of the initial and replication sample for the analysis of
C4L*Q0 carrier frequency were combined by mega analysis: We
performed a logistic regression with case-control status as outcome
and C4L*Q0 carrier status and study (initial or replication) as
influential variables.
Sample size and power calculations were performed with the
statistics program ‘BiAS. fu¨r Windows’ version 8.03 (http://www.
bias-online.de/). For the other statistical calculations the statistics
program R was used [44].
Registration of smoking habits
Smoking behavior was registered at study entry. Due to missing
or indistinct information of smoking habits altogether 490 study
participants needed to be excluded from the stratified analysis for
smoking. A reported smoking status was available for 672
individuals of the LLI and for 503 controls. Current smokers
and recent ex-smokers (quit ,3 years ago) were combined as
‘smokers’ and compared to ‘non-smokers’ (never smokers and quit
$3 years ago). Only cigarette smokers were considered in the
analysis. More information about smoking is given in Supplemen-
tary Table S1a in File S1.
Results
The power of our study for replicating the difference in C4B*Q0
carrier frequency between the elderly and younger controls, as
seen in Hungarians and Icelandic people [36,37,45], was
calculated to be 100% for the effects in each of the three studies.
The frequencies for C4B copy numbers are given in Table 1 (for
C4A, C4S and C4L see Supplementary Table S2 in File S1). They
were similar to those previously described for populations of
European descent [17,37]. No difference in frequency distribution
was found between long-lived cases and younger controls
(p = 0.32). For the primary endpoint C4B*Q0 carrier state (zero
or one C4B gene in the diploid genome), no difference was found
between LLI and the whole group of younger controls (carrier
frequency LLI: 28.57%, carrier frequency controls: 25.43%,
p= 0.16; Table 2). Due to the wide age-range from 19 to
Table 1. Frequencies of C4B copy numbers (absolute numbers are in parentheses).
number of C4B
genes 0 1 2 3 4 5 6 7 p value
German sample cases (LLI); n = 728 2.34% (17) 26.24% (191) 65.38% (476) 5.49% (40) 0.27% (2) 0.14% (1) 0% (0) 0.14% (1)
controls; n = 920 2.28% (21) 23.15% (213) 70.00% (644) 4.35% (40) 0.22% (2) 0% (0) 0% (0) 0% (0) 0.32
European Americans* females; n = 385 2.3% (9) 25.7% (99) 64.9% (250) 6.8% (26) 0.3% (1)**
males; n = 128 3.9% (5) 30.5% (39) 58.6% (75) 7.0% (9) 0% (0)**
p value: p value for the comparison of allele frequencies between long-lived cases and younger controls (Fisher’s exact test).
*adapted from [17]; European American female and male controls.
**number of C4B genes $4.
doi:10.1371/journal.pone.0086188.t001
Table 2. Results of the comparison of Q0 carrier state for the C4B gene (absolute numbers are in parentheses).
age groups #45 y; n=299 46–60 y; n =361 61–75 y; n =260 94–100 y; n=275 .100 y; n =453 p value
C4B*Q0 carriers 23.08% (69) 28.81% (104) 23.46% (61) 28.36 (78) 28.70% (130)
p_contr_trend
= 0.85; p_case
= 0.93; p_trend = 0.17
25.43% (234; #45–75 y) 28.57% (208; 94–.100 y) p_case_contr = 0.16
p_contr_trend: p value for trend test of C4B*Q0 frequencies in the three control subgroups (Armitage trend test; secondary endpoint).
p_case: p value for the comparison of C4B*Q0 frequencies in the two case subgroups (Fisher’s exact test; secondary endpoint).
p_trend: p value for trend test of C4B*Q0 frequencies in all five age groups (Armitage trend test; secondary endpoint).
p_case_contr: p value for the comparison of C4B*Q0 frequencies between long-lived cases (whole sample) and all younger controls (Fisher’s exact test; primary
endpoint).
n = number; y = years.
doi:10.1371/journal.pone.0086188.t002
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110 years, the study sample was additionally divided into five
different subgroups (secondary endpoint analysis) (#45 years, 46–
60 years, 61–75 years, 94–100 years and .100 years). However,
no increasing or decreasing trend in C4B*Q0 carrier frequency was
observed for the five age subgroups (p value for trend in the
control subgroups: 0.85, p value for the comparison of the two
long-lived subgroups: 0.93, p value for trend over all five age
subgroups: 0.17) (Table 2). The frequencies varied from 23.08% to
28.81% between different age groups without a trend for age
(Figure 1). Since genetic variation may potentially influence the
longevity phenotype in men and women differently [46,47], we
also performed a sex-stratified analysis. Again, no significant
differences between age groups were detected (data not shown). To
evaluate whether differences in C4B*Q0 carrier frequencies would
be evident in smokers (as previously described in the study of
Szilagyi et al. 2008), we performed a stratified analysis for smokers
and non-smokers, but no significant differences were observed
(Figure 2). Furthermore, we changed our age grouping such that it
was concordant with that of Kramer et al. 1989 [36] and Arason
et al. 2003 [37] (Supplementary Table S3 in File S1). Still, no
significant difference was detected.
The investigation of C4A and C4S copy numbers did not yield a
significant difference between age groups (data not shown). In the
C4L analysis, however, C4L*Q0 demonstrated a different carrier
frequency between long-lived cases and younger controls (cases
5.08%, controls 9.12%; p= 0.003, p value for trend in the control
subgroups: 0.52, p value for the comparison of the two case
subgroups: 0.85, p value for trend over all five age subgroups:
0.004) (Table 3 and Supplementary Table S4 in File S1). The
difference between LLI and controls did not depend on gender or
smoking status (data not shown). We investigated an additional
sample of 714 German LLI and 890 younger controls, which had
a power of 86% to replicate our significant results for C4L*Q0.
Our primary endpoint analysis revealed a decrease in the C4L*Q0
carrier frequency with age (cases 7.84%, controls 10.00%). Those
differences were not statistically significant (p = 0.14), but a
significant trend was detected in our secondary endpoint analysis,
when the sample was divided into four different age subgroups
(#45 years, 46–60 years, 61–79 years and .91 years, p = 0.03)
(Table 4 and Supplementary Table S5 in File S1). When the case-
control groups were defined with the same age ranges as the initial
screening sample (94–108 and 61–75 years), only marginally
different results were obtained (see Supplementary Table S6 in
File S1). An additional analysis for males and females separately
revealed similar results (data not shown). When the data of the
initial and replication sample were combined as a mega analysis (a
meta analysis using the original data sets), no significant influence
of study (initial or replication) or interaction with C4L*Q0 carrier
status was found. However, C4L*Q0 carrier frequency was
significantly different between the combined cases and controls
(p = 0.002).
Discussion
The C4 gene size (C4S or C4L) or the copy numbers of total C4,
C4A, C4B genes may influence disease susceptibilities or the
immune response [15,16,18,27,28]. As carriers of unfavorable
genetic variants are affected by higher mortality, they are expected
to decrease in frequency in population strata of increasing age
[8,9]. Previously, an association between C4B copy number and
life span was reported for Hungarians [36,45] showing a decrease
of the C4B*Q0 carrier frequency with age from 32% to 10% [45].
This observation indicated that individuals with a low C4B copy
number could be selected out from the population due to their
increased disease mortality [15]. A replication experiment in an
independent Icelandic sample also showed a low C4B*Q0 carrier
frequency of 5% in the elderly [37]. However, in an Icelandic
follow-up study [30], a significant decrease with age was detected
for smokers only. In other samples from Italy, no statistically
significant differences in C4B*Q0 allele frequencies were observed
[40]. The last four studies had a power above 99% to replicate the
original C4B*Q0 association [36], irrespective of any interacting
effect of smoking. It has to be taken into account, however, that
overestimation of effect sizes is a common phenomenon in
Table 3. Results of the comparison of Q0 carrier state for the C4L gene (absolute numbers are in parentheses).
age groups #45 y; n=294 46–60 y; n=351 61–75 y; n =254 94–100 y; n =233 .100 y; n =416 p value
C4L*Q0 carriers 9.86% (29) 9.12% (32) 8.27% (21) 4.72 (11) 5.29% (22)
p_contr_trend
= 0.52; p_case
= 0.85; p_trend = 0.004
9.12% (82; #45–75 y) 5.08% (33; 94–.100 y) p_case_contr = 0.003
For abbreviations see legend to Table 2.
doi:10.1371/journal.pone.0086188.t003
Table 4. Replication study in additional German sample: Results of the comparison of Q0 carrier state for the C4L gene (absolute
numbers are in parentheses).
age groups #45 y; n=344 46–60 y; n =248 61–79 y; n=298 91–108 y; n =714* p value
C4L*Q0
carriers
11.92% (41) 10.08% (25) 7.72% (23) 7.84% (56) p_contr_trend
= 0.08; p_trend
= 0.03
10.00% (89; #45–79 y) p_case_contr = .14
For abbreviations see legend to Table 2.
p_trend: p value for trend test of C4B*Q0 frequencies in all four age groups (Armitage trend test; secondary endpoint).
*Due to the small number of centenarians in the replication sample we did not subdivide the case sample into a nonagenarian and centenarian subgroup.
doi:10.1371/journal.pone.0086188.t004
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discovery samples, which may cause subsequent studies to be
underpowered [48].
The previous inconsistent association observations prompted us
to investigate the role of C4 copy number variation in our large
German longevity sample, taking into consideration the smoking
status. No significant frequency differences for C4A, C4B and C4S
alleles and no influence of smoking status or gender were detected.
In the German sample, the C4B*Q0 carrier frequency for smokers
and non-smokers varied from 13.33% to 36.36% for the different
age groups without any correlation with age (Figure 2).
For a better comparison with the previous studies, we also
subdivided our cases and controls into five age subgroups. Again,
no consistent trend for increasing age and no threshold for lower
or higher C4B*Q0 carrier frequencies was seen. In particular, the
frequencies between nonagenarians and centenarians were very
similar.
Considering that our study had a power of 100% to replicate
the previous findings, our results suggest that in Germans, the
C4B*Q0 copy number plays no role in the ability to reach old age
and that smoking does not influence the C4B*Q0 status across age
groups as an interacting variable. However, one has to consider
that smoking behaviour in prevalence and quality is known to have
changed over time during the 20th century [49,50] and can also
vary between different populations. This may result in ‘‘smoking’’
meaning different things in different age groups and populations
leading to inconsistent findings. It has also to be taken into account
that life expectancy slightly differs between the three investigated
populations (Hungary 71.4 years, Germany 77.4 years, Iceland
79.4 years, life expectancies averaged over both sexes according to
the U.S. Census Bureau’s International Data Base; www.census.
gov/). Besides, the negative findings in Germans may be due to
population-specific effects, since longevity in different populations
is likely to be influenced by varying sets of interacting genetic and
environmental factors [51]. With respect to the current investiga-
tion, all populations analyzed so far have been of European
ancestry and are similar in their C4 gene variation [20,22].
Moreover, our German sample was more extensive and the 700
German LLI much older (94–110 years) compared to the
Hungarian (60–90 years) and Icelandic (60–93 years) old-age
groups. The elderly Hungarians and Icelanders, which showed a
significant decrease in the C4B*Q0 allele frequency, just comprised
482, 131, 58 and 25 individuals, respectively [30,36,37,45]. These
groups might therefore be prone to a large sampling variance or
could represent biased samples that do not yield adequately precise
estimates for the intended purposes [52]. This assumption is
supported by the observation that deviations in C4B*Q0 frequen-
cies – but without a decreasing trend with age – were seen for
those age groups of German smokers and non-smokers that
included only very few individuals (smokers: 61–75 years, n
number of centenarians in the 20, 20.00%; 94–110 years, n
number of centenarians in the 22, 36.36%; Figure 2a), (non-
smokers: #45 years, n number of centenarians in the 45, 13.33%;
61–75 years, n number of centenarians in the 98, 20.41%;
Figure 2b). Overall, our data confirm the negative association
result of the Italian centenarian study [40] and suggest that
C4B*Q0 copy number does not influence survival into old age.
For C4L, independent of gender or smoking status, a
significantly lower C4L*Q0 carrier frequency was observed for
the long-lived cases compared to younger controls, showing only
marginal frequency differences between the three control
subgroups on the one hand and between nonagenarians and
centenarians on the other. However, our significant case-control
association result for the C4L*Q0 allele as primary endpoint could
not be replicated in a second German longevity sample, although
the same trend towards a decrease in the frequency of C4L*Q0
carriers with age was observed together with a significant trend
over four different age groups. Interestingly, the age groups
#45 years and between 46 and 60 years show a similar C4L*Q0
carrier frequency of around 10 to 12% in contrast to a frequency
of around 7 to 8% in the age groups 61 to 79 years and above
91 years (due to the small number of centenarians in the
replication sample we did not divide the case sample into a
nonagenarian and centenarian subgroup). For the C4L*Q0
replication experiment, a very large analysis population was
investigated (1604 individuals), which had a power of 86% to
replicate our initial finding. However, it should be mentioned that
very often the detected effect size in the first pilot study is
considerably overestimated and therefore needs to be adjusted in
subsequent replications [48]. Regarding the observed frequency
difference for C4L*Q0 carriers in the replication sample (elderly
7.84%; young 10.00%), a sample size of 2825 old-aged cases (with
a case-control ratio of 1) would be required for 80% power.
Hence, for validation it may be necessary to enlarge sample sizes
in future studies or to perform meta-analyses across different
longevity populations [53].
To the best of our knowledge, little is known about the
association of C4L or C4L*Q0 with disease or other phenotypes.
The C4L variant was shown to be associated with less effective
gene transcription compared to the C4S variant, raising the
possibility of a negative epistatic effect on the expression of C4
proteins [18,22,54]. Consequently, the function of the classical
complement pathway may affect, via a changed equilibrium or
reduction of C4 gene products, complement-dependent patholog-
ical processes and hence might influence immunity and lifespan
[45]. As the presence of long C4 genes correlates with lower
plasma C4 protein concentrations [18,22], we hypothesize that
C4L deficiency in our LLI sample could result in a higher and
more balanced C4 protein expression leading to improved health
and prolonged life span.
With altogether more than 3000 individuals investigated our
study presents the largest C4 copy number investigation in human
longevity research to-date. Thus, our analysis results offer a
valuable reference point for further genetic studies and help
provide a balanced view of the obtained research evidences.
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